Longevity & Aging · Diets · Metabolic & Cardiometabolic
fasting or very-low-calorie diet reverses type 2 diabetes
In plain terms: Can a strict diet or fasting actually put type 2 diabetes into lasting remission, not just control it?
Part of: • Fasting & Time-Restricted Eating
Yes — substantial weight loss via very-low-calorie diet or carbohydrate restriction produces genuine, durable remission with beta-cell recovery in a meaningful fraction of people, though remission is weight-loss-driven not fasting-specific and often relapses if weight returns.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
Substantial weight loss through a very-low-calorie diet or carbohydrate restriction produces genuine type 2 diabetes remission, with beta-cell function and liver fat recovering: an eight-week 600-kcal diet normalised fasting glucose and first-phase insulin secretion, and a randomised trial reached 22.5 percent remission against 2.5 percent. Remission depends on keeping the weight off.
The evidence (15)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R 2011 · Diabetologia | observational | supports | moderate | Counterpoint: 8-week 600-kcal VLCD normalised fasting glucose, first-phase insulin secretion, and reduced pancreatic/hepatic fat — mechanistic proof of beta-cell recovery. |
| Leslie WS, Ford I, Sattar N, Hollingsworth KG, Adamson A, Sniehotta FF, McCombie L, Brosnahan N, Ross H, Mathers JC, Peters C, Thom G, Barnes A, Kean S, McIlvenna Y, Rodrigues A, Rehackova L, Zhyzhneuskaya S, Taylor R, Lean ME 2016 · BMC Fam Pract | mechanism | mixed | low | DiRECT protocol formalises twin-cycle hypothesis: ectopic liver/pancreas fat drives T2D, removable by about 15 kg loss to restore normoglycaemia. |
| Badrooj N, Esteghamati A, Djafarian K, Yekaninejad MS, Mohammadpour S, Dankoob V, Reyhan SK, Abbaszade M, Emamgholipour S, Shab-Bidar S 2026 · Endocrinol Diabetes Metab | RCT | supports | moderate | DIREM RCT (n=120): calorie-carbohydrate restriction (CCR) alone achieved diabetes remission in 22.5% vs 2.5% control (OR 11.7); combining CCR with intermittent fasting (IFCCR) achieved 30.0% remission (OR 18.1 vs control); IFCCR v |
| Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, Rothberg AE, le Roux CW, Rubino F, Schauer P, Taylor R, Twenefour D 2021 · Diabetes Care | observational | mixed | low | Consensus report defining terms, not a study: 'an international expert group was convened by the American Diabetes Association to propose nomenclature'; remission = 'HbA1c <6.5% (48 mmol/mol) measured at least 3 months after cessation of glucose-lowering pharmacotherapy'. No new data — review, zero weight. |
| Corrao S, Falcone F, Mirarchi L, Amodeo S, Calvo L 2025 · Diabetes Ther | observational | supports | low | Narrative review: T2D remission is 'increasingly recognised as an achievable target'; metabolic surgery has the largest effect, but intensive lifestyle interventions and pharmacotherapy (GLP-1 RAs, tirzepatide) also show promise |
| Wu R, Yang X, Zhou X, Xiao Z, Chen X, Zhou J, Li J, Yin Z, Lai X, Wang T, Li Q, Liu D 2025 · Front Endocrinol | RCT | supports | moderate | 3-yr follow-up of intermittent energy restriction: remission maintainable without ongoing intervention in normal-BMI subset, but relapse tracks weight regain. |
| Hallberg SJ, McKenzie AL, Williams PT, Bhanpuri NH, Peters AL, Campbell WW, Hazbun TL, Volk BM, McCarter JP, Phinney SD, Volek JS 2018 · Diabetes Ther | observational | supports | moderate | Virta 1-yr: very-low-carb continuous care lowered HbA1c and cut diabetes medication in most; 60% reversal metric but non-randomised, single-arm design. |
| Wang L, Liang C, Yu J, Zhang Y, Li H, Hu Y, Liu W, Qu X, Xie W, Wang X, Yuan H 2026 · Food Res Int | RCT | supports | low | Small crossover RCT: 7-day very-low-calorie high-fibre lead-in improved HbA1c and gut microbiota in newly-diagnosed T2D, supporting early-window reversibility. |
| Pescari D, Mihuta S, Bena A, Pui R, Paul C, Stoian D 2026 · Front Clin Diabetes Healthc | observational | supports | low | Mini-review synthesizing evidence that low-energy diets, Mediterranean pattern, ketogenic approaches, and time-restricted eating can induce T2D remission via reduced ectopic (visceral/hepatic) fat and improved insulin sensitivity |
| Athinarayanan SJ, Adams RN, Hallberg SJ, McKenzie AL, Bhanpuri NH, Campbell WW, Volek JS, Phinney SD, McCarter JP 2019 · Front Endocrinol | observational | supports | moderate | Virta 2-yr non-randomised: sustained HbA1c/medication reductions but attrition and no control arm limit remission claims; not ADA-defined remission off all drugs. |
| Lakhani HA, Biswas D, Kuruvila M, Chava MS, Raj K, Varghese JT, Swathi NL 2025 · Prim Care Diabetes | meta-analysis | mixed | moderate | Review: intermittent fasting and continuous caloric restriction give comparable glycemic/weight benefit — no clear superiority of fasting over calorie restriction. |
| Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow CM, Sattar N, Taylor R 2019 · Lancet Diabetes Endocrinol | RCT | supports | high | DiRECT 2-yr: 36% of VLCD intervention participants in remission vs 3% control, with 64% remission among those maintaining greater than 10 kg loss. |
| Yang X, Zhou J, Shao H, Huang B, Kang X, Wu R, Bian F, Hu M, Liu D 2023 · J Clin Endocrinol Metab | RCT | supports | moderate | Fasting-specific RCT: intermittent calorie-restricted (CMNT) diet achieved 47.2% ADA-defined remission at 12 months vs 2.8% control — direct fasting evidence. |
| Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Kelly T, Irvine K, Peters C, Zhyzhneuskaya S, Hollingsworth KG, Adamson AJ, Sniehotta FF, Mathers JC, McIlvenna Y, Welsh P, McConnachie A, McIntosh A, Sattar N, Taylor R 2024 · Lancet Diabetes Endocrinol | observational | mixed | moderate | DiRECT 5-yr extension: remission fell to about 13% intervention vs 5% control as weight was regained, showing remission is real but durability wanes. |
| McKenzie AL, Athinarayanan SJ, Van Tieghem MR, Volk BM, Roberts CGP, Adams RN, Volek JS, Phinney SD, Hallberg SJ 2024 · Diabetes Res Clin Pract | observational | mixed | low | Virta 5-yr extension: benefits attenuated with heavy attrition (about 46% retained), tempering durable-remission claims from low-carb approach. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.